Expert Rev Resp Med. 2012;6(3):255-265. The acute effect of the combination oral sildenafil and inhaled treprostinil has also been assessed. Fifty patients with pulmonary hypertension of varying ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Six-minute walk distance improved over 52 weeks with ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Inhaled treprostinil significantly improved persistence, adherence and lowered risk for ...

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year ...

Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need. Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.

MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...

FDA’s approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILD YUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device ...

Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer Liquidia funds $10 million ...

Intravenous and subcutaneous infusions of treprostinil, as detailed above, are efficacious therapies in PAH but are not without problems. Similarly, the short half-life of iloprost necessitates a ...

MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today ...

Inhaled iloprost was recently approved as a treatment for severe pulmonary arterial hypertension in Europe, Australia and the US, but inhalation sessions of up to approximately 2 h per day are ...